Similar articles for PMID: 31704852

Year	Number of Results
2015	1
2016	7
2017	25
2018	50
2019	46
2020	27
2021	8
2022	6
2024	0

1

The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

Hirashima T, Kanai T, Suzuki H, Yoshida H, Matsushita A, Kawasumi H, Samejima Y, Noda Y, Nasu S, Tanaka A, Morishita N, Hashimoto S, Kawahara K, Tamura Y, Okamoto N, Tanaka T. Hirashima T, et al. Anticancer Res. 2019 Nov;39(11):6231-6240. doi: 10.21873/anticanres.13832. Anticancer Res. 2019. PMID: 31704852

2

Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors.

Hirashima T, Kanai T, Suzuki H, Yoshida H, Matsusita A, Kawasumi H, Nasu S, Tanaka A, Morishita N, Kawahara K, Tamura Y, Okamoto N. Hirashima T, et al. Anticancer Res. 2020 Dec;40(12):6971-6978. doi: 10.21873/anticanres.14721. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288591

3

Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors.

Kanai T, Suzuki H, Yoshida H, Matsushita A, Kawasumi H, Samejima Y, Noda Y, Nasu S, Tanaka A, Morishita N, Hashimoto S, Kawahara K, Tamura Y, Okamoto N, Tanaka T, Hirashima T. Kanai T, et al. Anticancer Res. 2020 May;40(5):2787-2793. doi: 10.21873/anticanres.14251. Anticancer Res. 2020. PMID: 32366425

4

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ. Chen L, et al. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5. Int J Radiat Oncol Biol Phys. 2018. PMID: 29485071

5

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.

Katsurada M, Nagano T, Tachihara M, Kiriu T, Furukawa K, Koyama K, Otoshi T, Sekiya R, Hazama D, Tamura D, Nakata K, Katsurada N, Yamamoto M, Kobayashi K, Nishimura Y. Katsurada M, et al. Anticancer Res. 2019 Feb;39(2):815-825. doi: 10.21873/anticanres.13180. Anticancer Res. 2019. PMID: 30711962

6

Case report: reinitiating pembrolizumab treatment after small bowel perforation.

Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Beck TN, et al. BMC Cancer. 2019 Apr 24;19(1):379. doi: 10.1186/s12885-019-5577-5. BMC Cancer. 2019. PMID: 31018834 Free PMC article.

7

Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.

Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Okada N, et al. Sci Rep. 2020 Aug 13;10(1):13773. doi: 10.1038/s41598-020-70743-2. Sci Rep. 2020. PMID: 32792640 Free PMC article.

8

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.

Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Nakanishi Y, et al. Respir Investig. 2019 Sep;57(5):451-459. doi: 10.1016/j.resinv.2019.05.002. Epub 2019 Jun 24. Respir Investig. 2019. PMID: 31248832

9

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.

Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, Tucker M, Lee SE, Light DE, Gossai A, Sorg RA, Torres AZ, Patel P, Blumenthal GM, Pazdur R. Khozin S, et al. Oncologist. 2018 Mar;23(3):328-336. doi: 10.1634/theoncologist.2017-0353. Epub 2018 Jan 9. Oncologist. 2018. PMID: 29317551 Free PMC article.

10

Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.

Kubo S, Kobayashi N, Somekawa K, Hirata M, Kamimaki C, Aiko H, Katakura S, Teranishi S, Watanabe K, Hara YU, Yamamoto M, Kudo M, Kaneko T. Kubo S, et al. Anticancer Res. 2020 Jul;40(7):3889-3896. doi: 10.21873/anticanres.14379. Anticancer Res. 2020. PMID: 32620629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

150 results

Results by year